E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Protozoal infection caused by any of the five species of Plasmodia and transmitted by anopheline mosquitoes |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Parasitic Diseases [C03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the peripheral parasitological clearance rate of Azithromycin/chloroquine (AZCQ) on Day 28 (Polymerase chain-reaction [PCR] corrected) following first dose of 3-day dosing regimen of AZCQ in asymptomatic pregnant women with Plasmodium falciparum parasitemia. |
|
E.2.2 | Secondary objectives of the trial |
Parasitological clearance rates (PCR corrected) at Days 7, 14, 21, 35, and 42 post first dose of study medication.
Parasitological clearance rates (PCR uncorrected) at Days 7, 14, 21, 28, 35, and 42 post first dose of study medication.
Pharmacokinetic exposure of AZCQ.
Safety and tolerability of AZCQ |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Primigravidae and secundigravidae pregnant women at greater than or equal to (>=) 14 and less than or equal to (<=) 30 weeks of gestational age (confirmed by ultrasound examination).
2. Evidence of asymptomatic parasitemia with Plasmodium falciparum monoinfection (confirmed by microscopy) with parasite counts in the range of 80-100,000 per microliter on thick blood smears.
3. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative if a subject is less than [<] 18 years of age) has been informed of all pertinent aspects of the study and that all questions by the subject have been sufficiently answered. Assent will be obtained from subjects <18 years of age.
4. Subjects willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
5. Subjects supervised for treatment administration, and available for all follow up visits as per protocol.
|
|
E.4 | Principal exclusion criteria |
1. Age <16 years old or greater than (>)35 years old.
2. Multiple gestations (more than one fetus) as per the ultrasound results at screening.
3. Clinical symptoms of malaria.
4. Hemoglobin <8 gram per deciliter (g/dL).
5. Any condition requiring hospitalization or evidence of severe concomitant infection at time of presentation.
6. Use of antimalarial drugs in previous 4 weeks.
7. History of convulsions, hypertension, diabetes or any other chronic illness that may
adversely affect fetal growth and viability.
8. Inability to tolerate oral treatment in tablet form.
9. Known allergy to the study drugs (Azithromycin [AZ], Chloroquine [CQ], and Sulfadoxine-pyrimethamine [SP]) or to any macrolides or sulphonamides.
10. Present history of smoking or alcohol or drug abuse since becoming pregnant.
11. Participation in other studies within 30 days before the current study begins and/or during study participation.
12. Inability to comprehend and/or unwillingness to follow the study protocol.
13. Concurrent participation in another investigational study.
14. Previously randomized in this study.
15. Requirement to use medication during the study that might interfere with the evaluation of the study drug (for example, trimethoprim-sulfamethoxazole use in subjects positive for HIV infection) or is contra-indicated during pregnancy per package inserts.
16. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that increase the risk associated with study participation or investigational product administration or interfer with the interpretation of study results and, made the subject inappropriate for entry into this study
17. Evidence of current obstetric complications that adversely impacted the pregnancy and/or fetal outcomes, including presence of congenital anomalies, placenta previa or abruption.
18. Known severe sickle cell (SS) disease or sickle-hemoglobin C (SC) anemia.
19. Known family history of prolonged QT syndrome, serious ventricular arrhythmia, or sudden cardiac death. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentage of Subjects With Parasitological Response (PCR corrected) at Day 28 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Percentage of Subjects With Parasitological Response (PCR corrected) Day 7, 14, 21, 35, and 42
Percentage of Subjects With Parasitological Response (PCR uncorrected) Days 7, 14, 21, 28, 35, and 42
Plasmodium falciparum Parasite Count Days 7, 14, 21, 28, 35, and 42 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Day 7, 14, 21, 35, and 42
Days 7, 14, 21, 28, 35, and 42 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Benin |
Kenya |
Malawi |
Tanzania, United Republic of |
Uganda |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 17 |
E.8.9.2 | In all countries concerned by the trial days | 19 |